The West Pharmaceuticals stock has fallen 10% in the past two months, with analysts estimating it could be around 50% lower by the end of the year.
The company’s stock has also been hit hard by the Brexit uncertainty, with investors worried about its future in the UK.
However, analysts think the company could rebound, with some predicting a rebound in profits and sales.
The stock is currently trading at around $10.45.
West Pharmaceutical is owned by drug giant AstraZeneca, which is the largest pharmaceutical company in the world.
The pharmaceutical company was founded in 1974 and has been a leader in the development of new drugs and therapies, especially in the area of Alzheimer’s disease.
The firm has more than 20,000 employees in the US, Europe and Asia, as well as over 500 facilities worldwide.
In February 2017, AstraZac and West Pharmaceutical announced that they would merge to form a global pharmaceutical company.
The merger has been delayed until 2024, but it is likely that the merger will be completed within the next few years.
West Pharmaceuticals CEO, James Gorman, has previously said that he does not expect the company to reach its financial goals.
West has recently made an investment in the global health care startup MedPage Today, which aims to “provide a global network of patient-centered, cost-effective health care technology solutions to the global healthcare industry.”
West Pharma shares fell 0.3% in London on Friday. “
I’m confident that he will lead West to success in the years ahead and deliver a long-term return for investors, shareholders and our employees.”
West Pharma shares fell 0.3% in London on Friday.
Read more West Pharmaceutical stocks to trade down on Wall Street as Brexit uncertainty looms.